MADISON, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Wyeth announced today that the jury in the cases of Brigitte DeMonja v. Wyeth and Dorothy Parkin v. Wyeth in the Philadelphia Court of Common Pleas found in favor of the Company in the Parkin case.
In the DeMonja case, the jury assessed total damages in the amount of $88,000. Wyeth announced that it intends to appeal this verdict. Three other plaintiffs were originally part of this trial group. Those plaintiffs all voluntarily chose to dismiss their cases before trial.
The trial began on October 17, 2005 before The Honorable Matthew Carrafiello. The plaintiffs alleged heart valve injury from the use of the diet drugs Pondimin, a drug once marketed by Wyeth.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
WyethCONTACT: Media Contacts, Douglas Petkus, Wyeth, 973-660-5218, orChristopher Garland, Wyeth Pharmaceuticals, 484-865-6323; or InvestorContact, Justin Victoria, Wyeth, 973-660-5340
Web site: http://www.wyeth.com/
